Rat jugular vein hemostasis - a new model for testing antithrombotic agents

Raake, W; Elling, H

doi:10.1016/0049-3848(89)90116-3

Cited by 23 publications

(12 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, given the negligible effect of LMWH on standard hemostatic tests, the only way to estimate the clinical activity of these fractionated heparins has been by measuring their ability to inhibit factor Xa. Although many of the studies did demonstrate a correlation between peak anti‐Xa activity and antithrombotic effect after IV administration in acute studies, this finding was not demonstrated in other animal studies that included SC administration or evaluation of different fractions of heparin 8–14,16–18 . Additionally, before our study, there were no animal model studies that evaluated antithrombotic effect when anti‐Xa activity would be expected to be at its lowest (trough).…”

Section: Discussionmentioning

confidence: 98%

Antithrombotic Effect of Enoxaparin in Clinically Healthy Cats: A Venous Stasis Model

Wiele

Hogan

Green

et al. 2010

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Systemic arterial thromboembolic events are a serious complication of cardiac disease in cats. Objectives: To determine if enoxaparin induces an antithrombotic effect in cats at a dosage of 1 mg/kg SC q12h and if this antithrombotic effect is predicted by anti-Xa activity.Animals: Fourteen clinically healthy cats were divided into 3 groups: control (4 cats), treated and assessed at 4 hours (5 cats), and treated and assessed at 12 hours (5 cats).Methods: A venous stasis model was used and the extent of thrombus formation estimated by measuring thrombus weight and accretion of

show abstract

Section: Discussionmentioning

confidence: 98%

Antithrombotic Effect of Enoxaparin in Clinically Healthy Cats: A Venous Stasis Model

Wiele

Hogan

Green

et al. 2010

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…To evaluate the antithrombotic activity, an animal model of venous thrombosis in rats was used. 4 An occluding thrombus was produced by repeated clamping of the rat jugular vein. The gradual reduction in blood flow was measured by Doppler sonography as introduced originally by Harbauer et al 5 The number of clampings causing complete occlusion of the vessel was taken as a measure of the antithrombotic activity.…”

Section: Jugular Vein Thrombosis Modelmentioning

confidence: 99%

“…In these areas thrombi consisted mainly of platelets that adhered to the endothelium. 4,7 In the prevention of postoperative thromboembolism the subcutaneous injection is the standard route of administration for heparin and low molecular weight heparins. Therefore, it was of interest to follow the dura- tion of action of the bis-aldonic acid amides in comparison to heparin after subcutaneous injections.…”

Section: Jugular Vein Thrombosis Modelmentioning

confidence: 99%

“…For the routine screening of the antithrombotic effects of the bis-aldonic acid amides, we used a recently developed thrombosis model in rats. 4 This animal model has been found to give constant results in testing a broad range of antithrombotic substances. These include heparin, low molecular weight heparins, heparan sulfates, dermatan sulfates, hirudin, and coumarins.…”

Section: Fig 3 Duration Of Action (Hrs) Of Aprosulate Lw 10121 Hementioning

confidence: 99%

See 1 more Smart Citation

Derivatives of Bis-Aldonic Acid Amides and Their Anticoagulant and Antithrombotic Properties

Raake

Klauser²,

Elling³

et al. 1994

Semin Thromb Hemost

View full text Add to dashboard Cite

Aprosulate sodium was the first representative of a new class of synthetic polyanions showing antithrombotic efficacy in different animal models. In several clinical trails (Phase I) in human volunteers aprosulate demonstrated anticoagulant properties, too. Searching for other active substances of similar structure, a series of bis-aldonic acid amides were synthesized. These compounds exhibited interesting antithrombotic and anticoagulant activities. The pharmacodynamic activities of the compounds LW 10121, LW 10125, LW 10114, 10244, and LW 10168 are summarized in this article. These substances prolonged the APTT to 150% of the blank values at concentrations of 1.5 to 13.5 micrograms/mL. The thrombin time and anti-Xa test were only slightly influenced by concentrations up to 100 micrograms/mL. All compounds were investigated in a jugular vein hemostasis model in rats to examine their antithrombotic potential. They all had an antithrombotic activity lower than aprosulate, except compound LW 10121, which seemed to be a little more active. The subcutaneous injection of 10 mg/kg LW 10121 resulted in a longer duration of action than aprosulate and heparin. On the basis of the chemical structure and the profile of action, it is assumed that the new compounds may possess the same mode of action as aprosulate, but the mechanism of action may be different from heparin and low molecular weight heparins.

show abstract

“…The rat jugular vein clamping thrombosis (JVT) model 13 was used to evaluate the antithrombotic effects of the agent mixtures. After the completion of the rat tail transection bleeding model, the JVT model began 50 minutes after the initial IV injection.…”

Section: Methodsmentioning

confidence: 99%

Interactions of Oversulfated Chondroitin Sulfate (OSCS) From Different Sources With Unfractionated Heparin

Gray

Litinas

Jeske

et al. 2012

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

In 2008, oversulfated chondroitin sulfate (OSCS) was identified as the main contaminant in recalled heparin. Oversulfated chondroitin sulfate can be prepared from bovine (B), porcine (P), shark (Sh), or skate (S) origin and may produce changes in the antithrombotic, bleeding, and hemodynamic profile of heparins. This study examines the interactions of various OSCSs on heparin in animal models of thrombosis and bleeding, as well as on the anticoagulant and antiprotease effects in in vitro assays. Mixtures of 70% unfractionated heparin (UFH) with 30% OSCS from different sources were tested. In the in vitro activated partial thromboplastin time (aPTT) assay, all contaminant mixtures showed a decrease in clotting times. In addition, a significant increase in bleeding time compared to the control (UFH/saline) was observed. In the thrombosis model, no significant differences were observed. The OSCSs significantly increased anti-Xa activity in ex vivo blood samples. These results indicate that various sources of OSCS affect the hemostatic properties of heparin.

show abstract

Rat jugular vein hemostasis - a new model for testing antithrombotic agents

Cited by 23 publications

References 4 publications

Antithrombotic Effect of Enoxaparin in Clinically Healthy Cats: A Venous Stasis Model

Antithrombotic Effect of Enoxaparin in Clinically Healthy Cats: A Venous Stasis Model

Derivatives of Bis-Aldonic Acid Amides and Their Anticoagulant and Antithrombotic Properties

Interactions of Oversulfated Chondroitin Sulfate (OSCS) From Different Sources With Unfractionated Heparin

Contact Info

Product

Resources

About